Discussion
Treatment with Soliris (eculizumab) substantially reduces the risk and frequency of relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against the aquaporin-4 (AQP4) protein. That’s according to a systematic review of published studies reporting results from clinical trials testing Soliris in this…